Journals / Türk Onkoloji Dergisi / 2022 / Cilt: 37 - Sayı: 2

Epidemiological Markers in Adult Glial Tumors: A Single-Center Experience and The Utility of the Classification System

Pages
105–114
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The development of more practical and accessible methods in addition to standardized, rapid, and reliable methods for testing multiple markers at an acceptable cost is urgently needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE This study aimed to investigate the etiology of gliomas and determine the utility of the World Health Organization (WHO) classification of central nervous system tumors.
📊
Key Findings & Data:METHODS Patients aged ≥18 years who underwent surgery or were followed up for glial tumors between January 2017 and January 2020 and whose pathology reports indicated grade II-IV gliomas were included in the study.
💡
Conclusion & Impact:The development of more practical and accessible methods in addition to standardized, rapid, and reliable methods for testing multiple markers at an acceptable cost is urgently needed.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE This study aimed to investigate the etiology of gliomas and determine the utility of the World Health Organization (WHO) classification of central nervous system tumors. METHODS Patients aged ≥18 years who underwent surgery or were followed up for glial tumors between January 2017 and January 2020 and whose pathology reports indicated grade II-IV gliomas were included in the study. Patients with missing data, pathology results incompatible with grade II-IV gliomas, and unavail- able standard molecular/genetic tumor profiles were excluded from the study. RESULTS The results of the standard histopathological and molecular/genetic analyses were evaluated retrospec- tively without any additional examinations. Data from 259 patients were evaluated. Of these, 8 patients who did not meet the criteria for glioma pathology and 27 patients with not otherwise specified molecu- lar pathological examination results were excluded from the study. Patients were evaluated in detail re- garding demographic and admission data, pathology analysis, potential risk factors, and survival results. CONCLUSION Many factors, particularly high blood glucose levels, sedentary lifestyle, and radiofrequency elec- tromagnetic field exposure, appear to have a relationship with glioma etiology. There is a major het- erogeneity and lack of standardized efficient laboratory procedures that may interfere with reliable standard molecular results. “False positive” molecular markers consist a major classification issue and methods that reflect the requirements of the WHO classification may themselves be inadequate to es- tablish a profile with adequate sensitivity. The development of more practical and accessible methods in addition to standardized, rapid, and reliable methods for testing multiple markers at an acceptable cost is urgently needed.

🔖

Cite This Article

BAYATLI, E., TETİK, B., BÜYÜKTEPE, M., TOKDEMİR, N., GÜNER, Y. E., GÜNEY, Y., UĞUR, H. Ç. (2022). Epidemiological Markers in Adult Glial Tumors: A Single-Center Experience and The Utility of the Classification System. Türk Onkoloji Dergisi, Cilt: 37 - Sayı: 2, 105–114. https://ajindex.com/articles/639071

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17(Suppl 4):iv1–iv62
  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Revised 4th ed. Lyon: IARC; 2016. p. 10–122
  3. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Fi- garella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23(8):1231–51
  4. Howlader N, Noone AM, Krapcho M. SEER cancer statistics review, 1975–2011. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2011. Ac- cessed Jul 11, 2021
  5. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet 2012;205(12):613–21
  6. Sadetzki S, Bruchim R, Oberman B, Armstrong GN, Lau CC, Claus EB, et al. Description of selected char- acteristics of familial glioma patients - results from the Gliogene Consortium. Eur J Cancer 2013;49(6):1335– 45
  7. Linet MS, Slovis TL, Miller DL, Kleinerman R, Lee C, Rajaraman P, et al. Cancer risks associated with exter- nal radiation from diagnostic imaging procedures. CA Cancer J Clin 2012;62(2):75–100
  8. Grell K, Frederiksen K, Schüz J, Cardis E, Armstrong B, Siemiatycki J, et al. The intracranial distribution of gliomas in relation to exposure from mobile phones: analyses from the INTERPHONE study. Am J Epi- demiol 2016;184(11):818–28
  9. Moore SC, Rajaraman P, Dubrow R, Darefsky AS, Koebnick C, Hollenbeck A, et al. Height, body mass index, and physical activity in relation to glioma risk. Cancer Res 2009;69(21):8349–55
  10. Wang P, Hou C, Li W, Zhou D. Dietary nitrite and ni- trate is not associated with adult glioma risk: a meta analysis. Int J ClinExp Med 2016;9:8334–40
  11. Chaichana KL, McGirt MJ, Woodworth GF, Datoo G, Tamargo RJ, Weingart J, et al. Persistent outpatient hyperglycemia is independently associated with sur- vival, recurrence and malignant degeneration follow- ing surgery for hemispheric low grade gliomas. Neurol Res 2010;32(4):442–8
  12. Gonzalez CA, Riboli E. Diet and cancer prevention: Contributions from the European Prospective Inves- tigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 2010;46(14):2555–62
  13. Li HX, Peng XX, Zong Q, Zhang K, Wang MX, Liu YZ, et al. Cigarette smoking and risk of adult glioma: a meta-analysis of 24 observational studies involving more than 2